Mer­ck’s glo­ri­ous vic­to­ry in lung can­cer marks a Russ­ian win­ter for Bris­tol-My­ers

Sun­day was check­point in­hibitor day at ES­MO, with the three big play­ers now in the mar­ket out­lin­ing how they’re lin­ing up in the block­buster field of lung can­cer ther­a­py. Mer­ck was left in the en­vi­able po­si­tion of dri­ving home some im­pres­sive re­sults from its clin­i­cal study while Bris­tol-My­ers Squibb had to try to put its mis­er­able out­comes in a some­what pos­i­tive con­text and a de­ter­mined Roche/Genen­tech team an­gled in on its niche.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.